Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Scholar Rock Holding Corp (SRRK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress"
05/09/2023 8-K Quarterly results
Docs: "Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress"
11/14/2022 8-K Quarterly results
Docs: "Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress"
08/08/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/07/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress"
03/09/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress"
08/07/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "Scholar Rock Reports First Quarter 2020 Financial Results and Highlights Business Progress"
03/12/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/14/2019 8-K Quarterly results
Docs: "Scholar Rock Reports Second Quarter 2019 Financial Results and Highlights Business Progress CAMBRIDGE, Mass., Aug. 14, 2019 -- Scholar Rock Holding Corporation , a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the quarter ended June 30, 2019 and highlighted recent progress and upcoming milestones for its pipeline programs. “Throughout the first half of 2019, we made significant progress both clinically and financially as we advanced SRK-015 into a Phase 2 trial in SMA, SRK-181 towards the initiation of a Phase 1 trial in cancer immunotherapy in mid-2020, as well as successfully completed a follow-on offering to ensure that we are well-capitalized to support ..."
05/14/2019 8-K Quarterly results
Docs: "Scholar Rock Reports First Quarter 2019 Financial Results and Highlights Business Progress CAMBRIDGE, Mass., May 14, 2019 -- Scholar Rock Holding Corporation , a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the quarter ended March 31, 2019 and highlighted recent progress and upcoming milestones for its pipeline programs. “2019 is off to a great start with the initiation of patient dosing in our Phase 2 TOPAZ trial of SRK-015 in SMA and the presentation of additional preclinical data outlining the potential of SRK-181 to expand the number of cancer patients who can benefit from checkpoint blockade therapies,” said Nagesh Mahanthappa, Ph.D., President and CEO..."
11/08/2018 8-K Quarterly results
Docs: "Scholar Rock Reports Third Quarter 2018 Financial Results and Highlights Business Progress CAMBRIDGE, Mass., Nov. 08, 2018 -- Scholar Rock Holding Corporation , a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the third quarter ended September 30, 2018 and highlighted recent progress and upcoming milestones for its pipeline programs. “We continue to make important progress with our pipeline having now completed enrollment in the multiple ascending dose portion of the ongoing Phase 1 clinical trial for SRK-015 with interim results and the initiation of a Phase 2 proof-of-concept study in patients with Spinal Muscular Atrophy expected in the first quarter of 20..."
08/08/2018 8-K Quarterly results
Docs: "Scholar Rock Reports Second Quarter 2018 Financial Results and Updates on Business Progress"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy